News

Two PD-L1 tests, SP263 and 22C3, show high agreement & effectively identify patients with early-stage non–small cell lung cancer who are likely to benefit from adjuvant atezolizumab.

The investigational new drug application of lacutamab, a novel drug for advanced T-cell lymphoma, was put on partial clinical hold after the death of a patient last year.

As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.

A study evaluating healthcare expenses identified lisocabtagene maraleucel as a cost-effective second-line treatment for patients with diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.

The completion of the phase 1 trial is a crucial step toward making DOC1021 available to all patients with glioblastoma multiforme.

Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.

Here is a look back at the FDA happenings from the month of December 2023.

In a phase 1 study of 10 evaluable patients with refractory/relapsed malignant pleural mesothelioma, the median overall survival was 17.6 months for patients treated with the combination of galinpepimut-S and nivolumab.

In an interview with Targeted Oncology, Francis P. Worden, MD, shed light on the evolving landscape of advanced thyroid cancer treatment, offering valuable insights into the available options.

The FDA did not fully approve sotorasib for the treatment of patients with KRAS G12C-mutated non–small cell lung cancer.

Leticia Nogueira, PhD, MPH, discusses the vulnerabilities and hazards that patients with cancer experience due to climate change.

The phase 1/2 CaRe PC trial evaluating INKmune, a biologic therapy, in male patients with metastatic castration-resistant prostate cancer has dosed its first patient.

In an interview with Targeted Oncology, James Zou, PhD, provided an overview of AI and machine learning applications in oncology.

Leticia Nogueira, PhD, MPH, discusses the cancer risks that fossil fuel consumption and climate change present.

In an interview with Targeted Oncology, Jennifer A. Woyach, MD, discussed updated results from the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma following treatment with a covalent Bruton tyrosine kinase inhibitor.

In an interview with Targeted Oncology, Daniel Baker, PhD candidate at the University of Pennsylvania, discussed the growing role for CAR T-cell therapies outside of the oncology field.

Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

In an interview with Targeted Oncology, Marcelen Rosenscheg, MD, discussed some of the methods that are used to treat pain in patients with cancer and the importance of such research.

Jonathan W. Riess, MD, medical director of thoracic oncology, University of California, Davis Comprehensive Cancer Center, discusses the phase 1b FAVOUR trial of furmonertinib in patients with advanced non–small cell lung cancer harboring EGFR Exon20 insertion mutations.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

Manmeet Ahluwalia, MD, discusses the progress and initiatives of the Cancer Moonshot program.

Susan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.

New treatments, including luspatercept-aamt, have been added to the treatment algorithm of patients with low-risk myelodysplastic syndrome in 2020.

These FDA approvals display a relentless pursuit of innovation in oncology, empowering oncologists with increasingly sophisticated treatment to help navigate and manage cancer’s complexities.

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.

In an interview with Targeted Oncology, Daniel Wolff, MD, discussed findings from the phase 2 AGAVE-201 trial evaluating axatilimab as a potential treatment option for patients with chronic graft-vs-host disease.

Shannon Westin, MD, MPH, FACOG, discusses her hopes following the presentation of promising data from the phase 3 DUO-E trial of durvalumab plus chemotherapy followed by durvalumab and olaparib maintenance in patients with newly diagnosed advanced or recurrent endometrial cancer.